Targeted Radionuclide Therapy (TRNT) using therapeutic radiopharmaceuticals is emerging fast as a complementary modality for the treatment of cancer. The beta-emitting radionuclides 90Y and 188Re have ...
The radiopharmaceutical consists of a radioactive molecule – in this case terbium-161 linked to a ligand. This ligand recognises proteins on the tumour cell, allowing highly targeted cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results